EUCTR2013-003083-31-GR进行中（未招募）不适用
Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Brimonidine 2 mg/ml Eye Drops vs. Alphagan™ Eye Drops in Patients with Open Angle Glaucoma or Ocular Hypertension - Comparative Phase III Trial between two formulations of Brimonidine 2 mg/ml Eye Drops
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients being male or female, of any race and =18 years of age; diagnosed of unilateral or bilateral open angle glaucoma or ocular hypertension;
- •-on treatment with Alphagan for at least 4 weeks;
- •-on treatment with an IOP =21 mmHg measured as the mean of both eyes at two measurements at least one hour apart;
- •-best-corrected visual acuity =20 of 100 corresponding to logMAR of 0.7 in both eyes; in case of women, postmenopausal (>12 months without menstrual bleeding), surgically sterilized, or on use of effective birth control measures;
- •-expected by the investigator that IOP would remain controlled under the investigational treatments without optic nerve damage or progression of visual field loss;
- •-able to understand the requirements of the clinical trial and to agree to return for the required follow-up visits;
- •-willing to provide voluntary written informed consent and data protection declaration before any clinical trial related procedure is performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 85
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 85
排除标准
- •-Patients with a history of chronic or recurrent inflammatory eye disease, ocular trauma or infections;
- •-narrow-angle/angle-closure glaucoma;
- •-corneal abnormalities that will preclude accurate IOP reading with an aplanation tonometer.
- •-clinically significant or progressive retinal disease;
- •-intraocular surgery within the past 6 months;
- •-ocular laser surgery within the past 3 months;
- •-best-corrected visual acuity worse than 0.7 logarithm of minimal angle of resolution (logMAR) score, extremely narrow or partially closed angle, cup/disk ratio >0.8;
- •-history of bronchial asthma, or severe chronic obstructive pulmonary disease; reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
- •treatment with local or systemic corticosteroids;
- •-inability to discontinue the use of glucocorticoid medications;
- •-not receiving stable doses of any medication that could affect IOP for 30 days before the beginning of the clinical trial (e.g. clonidine);
- •-monoamine oxidase (MAO) inhibitor therapy and patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin);
- •-a history of allergic hypersensitivity or poor tolerance to any component of the eye drop solution used in this clinical trial or a contraindication of ß-adrenergic receptor antagonists due to systemic disease;
- •severe or unstable and uncontrolled cardiovascular disease;
- •depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans;
- •-hepatic or renal impairment;
- •-sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock;
- •-pregnancy or breast-feeding or childbearing potential not protected by a highly effective contraceptive method of birth control;
- •-current participation or not yet completed period of at least 30 days since ending other investigational device or drug trial(s);
- •-unwillingness or inability to comply with the clinical trial procedures;
- •-unwillingness to consent to storage, saving and transmission of pseudonymous medical data for clinical trial reasons;
- •-who are legally incapacitated,
- •-who are legally detained in an official institute.
- •Patients requiring bilateral IOP-reducing therapy are treated in both eyes, but only the eye(s) that fulfil(s) all of the inclusion criteria and none of the exclusion criteria are designated as clinical trial eye(s). An eye not meeting all inclusion criteria but having none of the exclusion criteria may be treated with the clinical trial drug at the discretion of the investigator
研究者
相似试验
进行中（未招募）
1 期
Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Travoprost 40 µg/ml Eye Drops vs. Travatan? Eye Drops in Patients with Primary Open Angle Glaucoma or Ocular HypertensioPrimary open angle glaucoma or intraocular hypertensionMedDRA version: 14.1Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaSystem Organ Class: 10015919 - Eye disordersEUCTR2012-000026-22-ESOmnivision GmbH
进行中（未招募）
不适用
Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combination Latanoprost 50 µg/ml and Timolol 5 mg/ml Eye Drops vs. Xalacom? Eye Drops in Patients with Primary Open Angle Glaucoma or Ocular HypertensioPrimary open angle glaucoma or intraocular hypertensionMedDRA version: 14.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.0Level: LLTClassification code 10036719Term: Primary open angle glaucomaSystem Organ Class: 10015919 - Eye disordersEUCTR2011-005339-15-ESOmnivision GmbH
进行中（未招募）
1 期
Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combination Travoprost 40 µg/ml and Timolol 5 mg/ml Eye Drops vs. DuoTrav? Eye Drops in Patients with Primary Open Angle Glaucoma or Ocular HypertensioOpen Angle Glaucoma or Ocular HypertensionMedDRA version: 18.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersMedDRA version: 18.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersEUCTR2012-000044-10-ESOMNIVISIO
进行中（未招募）
1 期
This study will evaluate and confirm that the efficacy and tolerability of the generic formulation Dorzo-Vision® sine Preservative-Free Eye Drops solution is not worse to the marketed preservative free formulation Trusopt® Eye Drops solution in Patients with Open Angle Glaucoma or Ocular Hypertension already on Treatment with IOP-lowering Drugs and Low Intraocular Pressure (IOP=21 mmHg)Open angle glaucoma or ocular hypertensionMedDRA version: 20.0Level: SOCClassification code 10015919Term: Eye disordersSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030348Term: Open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: PTClassification code 10030043Term: Ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2019-000913-35-GRBECRO (Cyprus) Ltd150
进行中（未招募）
1 期
Comparison of ADVAIR medication vs Salmeterol vs Albuterol in Asthma patients, assessing lung function and other measures of asthma control.AsthmaEUCTR2015-004865-10-Outside-EU/EEAGlaxoSmithKiline Research and Development LTD.547